Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
NCT ID: NCT00499993
Last Updated: 2019-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
63 participants
INTERVENTIONAL
2001-01-31
2003-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects
NCT00701363
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
NCT02493517
Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
NCT00216398
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
NCT00210457
Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
NCT00444873
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
lanreotide (Autogel formulation), duration of treatment 46-48 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients previously treated with radiotherapy
* Patients previously treated with somatostatin analogue except for a pre-surgical treatment not longer than 3 months
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ipsen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ipsen Medical Director
Role: STUDY_DIRECTOR
Ipsen
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ospedali Riuniti di Bergamo
Bergamo, , Italy
Ospedale Maggiore
Bologna, , Italy
Clinica Medica - Sezione II Medicina Endocrinologia
Brescia, , Italy
Università deglis Studi di Cagliari
Cagliari, , Italy
Ospedale Garibaldi
Catania, , Italy
Università degli Studi di Ferrara
Ferrara, , Italy
Università degli Studi di Firenze
Florence, , Italy
D.i.S.E.M. Dipartimento di Scienze Endocrinologiche e Metaboliche
Genova, , Italy
Istituto Auxologico
Milan, , Italy
Ospedale Maggiore IRCCS
Milan, , Italy
Ospedale di Niguarda Cà Granda
Milan, , Italy
Università "Federico II" di Napoli
Napoli, , Italy
Ospedale "S. Luigi Gonzaga"
Orbassano (TO), , Italy
Università degli Studi di Padova
Padua, , Italy
Azienda Ospedaliera "V. Cervello"
Palermo, , Italy
Ospedale Cisanello
Pisa, , Italy
Servizio di Endocrinologia
Reggio Emilia, , Italy
Università "La Sapienza" di Roma
Roma, , Italy
Policlinico Agostino Gemelli
Roma, , Italy
Istituto di Patologia Speciale Medica e Metodologia Clinica
Sassari, , Italy
Università degli Studi di Ancona, Ospedale Umberto I
Sede Di Torrette (AN) Ancona, , Italy
Ospedale Molinette
Torino, , Italy
Ospedale Cà Foncello
Treviso, , Italy
Ospedale Santa Maria della Misericordia
Udine, , Italy
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, Chiarini V, Cozzi R, Grottoli S, Mantero F, Bogazzi F, Terzolo M, Tita P, Boscani PF, Colao A. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest. 2009 Mar;32(3):202-9. doi: 10.1007/BF03346453.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A-93-52030-077
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.